Tirzepatide, a co-agonist of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors already approved in some countries as an antidiabetic and antiobesity agent, has also been assessed to treat individuals with MASH and fibrosis F2-F3. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.